Does the media prefer LEGN or MRVI?

In the previous week, Legend Biotech and Legend Biotech both had 5 articles in the media. Legend Biotech's average media sentiment score of 0.89 beat Maravai LifeSciences' score of 0.13 indicating that Legend Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MRVI or INDV?

In the previous week, Maravai LifeSciences had 1 more articles in the media than Indivior. MarketBeat recorded 5 mentions for Maravai LifeSciences and 4 mentions for Indivior. Indivior's average media sentiment score of 0.21 beat Maravai LifeSciences' score of 0.13 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Indivior 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, MRVI or MANE?

Veradermics has lower revenue, but higher earnings than Maravai LifeSciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maravai LifeSciences $204.73M 6.35 -$130.77M -$0.71 N/A Veradermics N/A N/A N/A N/A N/A

Does the media favor MRVI or MANE?

In the previous week, Maravai LifeSciences had 3 more articles in the media than Veradermics. MarketBeat recorded 5 mentions for Maravai LifeSciences and 2 mentions for Veradermics. Maravai LifeSciences' average media sentiment score of 0.13 beat Veradermics' score of 0.05 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Veradermics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AMRX or MRVI?

In the previous week, Amneal Pharmaceuticals had 5 more articles in the media than Maravai LifeSciences. MarketBeat recorded 10 mentions for Amneal Pharmaceuticals and 5 mentions for Maravai LifeSciences. Amneal Pharmaceuticals' average media sentiment score of 0.50 beat Maravai LifeSciences' score of 0.13 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MRVI or TVTX?

In the previous week, Travere Therapeutics had 7 more articles in the media than Maravai LifeSciences. MarketBeat recorded 12 mentions for Travere Therapeutics and 5 mentions for Maravai LifeSciences. Travere Therapeutics' average media sentiment score of 0.72 beat Maravai LifeSciences' score of 0.13 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Travere Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Maravai LifeSciences (MRVI) Competitors

$5.03 -0.05 (-0.94%)

As of 09:43 AM Eastern

Compare

MRVI vs. LEGN, INDV, MANE, AMRX, and TVTX

Should you buy Maravai LifeSciences stock or one of its competitors? MarketBeat compares Maravai LifeSciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Maravai LifeSciences include Legend Biotech (LEGN), Indivior (INDV), Veradermics (MANE), Amneal Pharmaceuticals (AMRX), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry.

How does Maravai LifeSciences compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Legend Biotech has a net margin of -21.98% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

In the previous week, Legend Biotech and Legend Biotech both had 5 articles in the media. Legend Biotech's average media sentiment score of 0.89 beat Maravai LifeSciences' score of 0.13 indicating that Legend Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Legend Biotech has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

Maravai LifeSciences has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	6.38	-$296.80M	-$0.68	N/A
Maravai LifeSciences	$204.73M	6.35	-$130.77M	-$0.71	N/A

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Legend Biotech presently has a consensus target price of $60.23, suggesting a potential upside of 70.53%. Maravai LifeSciences has a consensus target price of $5.50, suggesting a potential upside of 9.30%. Given Legend Biotech's stronger consensus rating and higher probable upside, equities research analysts clearly believe Legend Biotech is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Legend Biotech beats Maravai LifeSciences on 9 of the 15 factors compared between the two stocks.

How does Maravai LifeSciences compare to Indivior?

Maravai LifeSciences (NASDAQ:MRVI) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

In the previous week, Maravai LifeSciences had 1 more articles in the media than Indivior. MarketBeat recorded 5 mentions for Maravai LifeSciences and 4 mentions for Indivior. Indivior's average media sentiment score of 0.21 beat Maravai LifeSciences' score of 0.13 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Indivior	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 0.7% of Indivior shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Indivior has a net margin of 19.44% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Indivior	19.44%	-219.26%	29.40%

Maravai LifeSciences presently has a consensus price target of $5.50, suggesting a potential upside of 9.30%. Indivior has a consensus price target of $39.33, suggesting a potential upside of 2.68%. Given Maravai LifeSciences' higher possible upside, analysts clearly believe Maravai LifeSciences is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Indivior has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$204.73M	6.35	-$130.77M	-$0.71	N/A
Indivior	$1.24B	3.77	$210M	$1.95	19.64

Maravai LifeSciences has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Indivior has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

Summary

Indivior beats Maravai LifeSciences on 12 of the 17 factors compared between the two stocks.

How does Maravai LifeSciences compare to Veradermics?

Maravai LifeSciences (NASDAQ:MRVI) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Veradermics has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Veradermics' return on equity of 0.00% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Veradermics	N/A	N/A	N/A

Maravai LifeSciences currently has a consensus target price of $5.50, suggesting a potential upside of 9.30%. Veradermics has a consensus target price of $109.00, suggesting a potential upside of 15.65%. Given Veradermics' stronger consensus rating and higher possible upside, analysts plainly believe Veradermics is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Veradermics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

50.3% of Maravai LifeSciences shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Veradermics has lower revenue, but higher earnings than Maravai LifeSciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$204.73M	6.35	-$130.77M	-$0.71	N/A
Veradermics	N/A	N/A	N/A	N/A	N/A

In the previous week, Maravai LifeSciences had 3 more articles in the media than Veradermics. MarketBeat recorded 5 mentions for Maravai LifeSciences and 2 mentions for Veradermics. Maravai LifeSciences' average media sentiment score of 0.13 beat Veradermics' score of 0.05 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veradermics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Veradermics beats Maravai LifeSciences on 6 of the 11 factors compared between the two stocks.

How does Maravai LifeSciences compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Amneal Pharmaceuticals has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.05B	1.62	$72.06M	$0.38	40.82
Maravai LifeSciences	$204.73M	6.35	-$130.77M	-$0.71	N/A

Amneal Pharmaceuticals has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

Amneal Pharmaceuticals has a net margin of 4.01% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

Amneal Pharmaceuticals presently has a consensus target price of $15.80, suggesting a potential upside of 1.86%. Maravai LifeSciences has a consensus target price of $5.50, suggesting a potential upside of 9.30%. Given Maravai LifeSciences' higher probable upside, analysts plainly believe Maravai LifeSciences is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Amneal Pharmaceuticals had 5 more articles in the media than Maravai LifeSciences. MarketBeat recorded 10 mentions for Amneal Pharmaceuticals and 5 mentions for Maravai LifeSciences. Amneal Pharmaceuticals' average media sentiment score of 0.50 beat Maravai LifeSciences' score of 0.13 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Amneal Pharmaceuticals beats Maravai LifeSciences on 12 of the 16 factors compared between the two stocks.

How does Maravai LifeSciences compare to Travere Therapeutics?

Maravai LifeSciences (NASDAQ:MRVI) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Maravai LifeSciences has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

50.3% of Maravai LifeSciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 4.4% of Travere Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Travere Therapeutics has a net margin of -4.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Travere Therapeutics	-4.00%	-26.16%	-3.71%

Maravai LifeSciences currently has a consensus price target of $5.50, indicating a potential upside of 9.30%. Travere Therapeutics has a consensus price target of $48.92, indicating a potential upside of 3.71%. Given Maravai LifeSciences' higher probable upside, equities research analysts clearly believe Maravai LifeSciences is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Travere Therapeutics has higher revenue and earnings than Maravai LifeSciences. Travere Therapeutics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$204.73M	6.35	-$130.77M	-$0.71	N/A
Travere Therapeutics	$536.20M	8.18	-$25.55M	-$0.23	N/A

In the previous week, Travere Therapeutics had 7 more articles in the media than Maravai LifeSciences. MarketBeat recorded 12 mentions for Travere Therapeutics and 5 mentions for Maravai LifeSciences. Travere Therapeutics' average media sentiment score of 0.72 beat Maravai LifeSciences' score of 0.13 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Travere Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Travere Therapeutics beats Maravai LifeSciences on 12 of the 16 factors compared between the two stocks.

Get Maravai LifeSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRVI vs. The Competition

Export

Metric	Maravai LifeSciences	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.30B	$8.51B	$6.49B	$11.95B
Dividend Yield	N/A	2.49%	2.67%	5.61%
P/E Ratio	-7.11	16.10	24.40	23.63
Price / Sales	6.35	5.65	478.43	84.19
Price / Cash	12.18	17.40	43.05	54.72
Price / Book	3.45	3.54	10.30	6.70
Net Income	-$130.77M	$225.32M	$3.56B	$337.26M
7 Day Performance	0.84%	-3.30%	-3.01%	-2.46%
1 Month Performance	6.16%	1.87%	-0.39%	0.31%
1 Year Performance	120.70%	-4.00%	20.03%	23.15%

Maravai LifeSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRVI Maravai LifeSciences	2.5945 of 5 stars	$5.03 -0.9%	$5.50 +9.3%	+135.2%	$1.30B	$204.73M	N/A	610	Insider Trade
LEGN Legend Biotech	4.4111 of 5 stars	$31.21 +14.9%	$59.15 +89.6%	-7.4%	$4.74B	$1.14B	N/A	2,965
INDV Indivior	2.0689 of 5 stars	$33.28 -7.6%	$39.33 +18.2%	+178.2%	$4.39B	$1.24B	17.46	1,051	Insider Trade
MANE Veradermics	N/A	$100.83 -0.1%	$109.00 +8.1%	N/A	$4.26B	N/A	N/A	19
AMRX Amneal Pharmaceuticals	3.2975 of 5 stars	$12.74 -3.2%	$15.17 +19.0%	+96.2%	$4.20B	$3.05B	33.50	8,500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRVI) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maravai LifeSciences (MRVI) Competitors

MRVI vs. LEGN, INDV, MANE, AMRX, and TVTX

How does Maravai LifeSciences compare to Legend Biotech?

Summary

How does Maravai LifeSciences compare to Indivior?

Summary

How does Maravai LifeSciences compare to Veradermics?

Summary

How does Maravai LifeSciences compare to Amneal Pharmaceuticals?

Summary

How does Maravai LifeSciences compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRVI vs. The Competition

Maravai LifeSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maravai LifeSciences (MRVI) Competitors

MRVI vs. LEGN, INDV, MANE, AMRX, and TVTX

How does Maravai LifeSciences compare to Legend Biotech?

Is LEGN or MRVI more profitable?

Does the media prefer LEGN or MRVI?

Which has more volatility & risk, LEGN or MRVI?

Which has higher earnings & valuation, LEGN or MRVI?

Do insiders & institutionals hold more shares of LEGN or MRVI?

Do analysts recommend LEGN or MRVI?

Summary

How does Maravai LifeSciences compare to Indivior?

Does the media favor MRVI or INDV?

Do insiders and institutionals have more ownership in MRVI or INDV?

Is MRVI or INDV more profitable?

Do analysts recommend MRVI or INDV?

Which has preferable earnings and valuation, MRVI or INDV?

Which has more volatility and risk, MRVI or INDV?

Summary

How does Maravai LifeSciences compare to Veradermics?

Is MRVI or MANE more profitable?

Do analysts recommend MRVI or MANE?

Do institutionals and insiders hold more shares of MRVI or MANE?

Which has better earnings and valuation, MRVI or MANE?

Does the media favor MRVI or MANE?

Summary

How does Maravai LifeSciences compare to Amneal Pharmaceuticals?

Which has better earnings & valuation, AMRX or MRVI?

Which has more risk & volatility, AMRX or MRVI?

Is AMRX or MRVI more profitable?

Do analysts recommend AMRX or MRVI?

Does the media refer more to AMRX or MRVI?

Do insiders and institutionals hold more shares of AMRX or MRVI?

Summary

How does Maravai LifeSciences compare to Travere Therapeutics?

Which has more risk & volatility, MRVI or TVTX?

Do insiders & institutionals have more ownership in MRVI or TVTX?

Is MRVI or TVTX more profitable?

Do analysts rate MRVI or TVTX?

Which has stronger earnings and valuation, MRVI or TVTX?

Does the media prefer MRVI or TVTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRVI vs. The Competition

Maravai LifeSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools